163 related articles for article (PubMed ID: 38038755)
1. Early response monitoring during [
Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of
Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L
J Nucl Med; 2023 Feb; 64(2):221-226. PubMed ID: 36008120
[No Abstract] [Full Text] [Related]
3. The Prognostic Value of Posttreatment
Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
[No Abstract] [Full Text] [Related]
4.
John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L
J Nucl Med; 2023 Mar; 64(3):410-415. PubMed ID: 36215568
[No Abstract] [Full Text] [Related]
5. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
6.
Karimzadeh A; Heck M; Tauber R; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
J Nucl Med; 2023 Mar; 64(3):402-409. PubMed ID: 36137758
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
8. Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy.
Widjaja L; Werner RA; Krischke E; Christiansen H; Bengel FM; Bogdanova N; Derlin T
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):602-612. PubMed ID: 36136101
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Performance of RECIP 1.0 Based on [
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
[TBL] [Abstract][Full Text] [Related]
10. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [
Song H; Leonio MI; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Shah J; Bergstrom CP; Fan AC; Shah S; Khaki AR; Srinivas S; Iagaru A
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38635050
[TBL] [Abstract][Full Text] [Related]
11. A Single-Arm, Low-Dose, Prospective Study of
Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
[TBL] [Abstract][Full Text] [Related]
12. Early biochemical and radiographic response after one cycle of [
Cytawa W; Hendel R; Tomasik B; Weinzierl FX; Bley T; Jassem J; Schirbel A; Buck AK; Bundschuh RA; Hartrampf PE; Werner RA; Lapa C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3765-3776. PubMed ID: 37474735
[TBL] [Abstract][Full Text] [Related]
13. SUV
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Schlötelburg W; Michalski K; Rowe SP; Pomper MG; Buck AK; Eberlein U; Werner RA
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3465-3474. PubMed ID: 37272956
[TBL] [Abstract][Full Text] [Related]
14. Combined
Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
[TBL] [Abstract][Full Text] [Related]
15. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
16. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO
Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963
[TBL] [Abstract][Full Text] [Related]
17. Clinical Experience with [
Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
[TBL] [Abstract][Full Text] [Related]
18. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with
Murthy V; Gafita A; Thin P; Nguyen K; Grogan T; Shen J; Drakaki A; Rettig M; Czernin J; Calais J
J Nucl Med; 2023 Nov; 64(11):1737-1743. PubMed ID: 37678927
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
Telli T; Tuncel M; Karabulut E; Aksoy S; Erman M; Akdogan B; Caglar M
Prostate; 2023 Jun; 83(8):792-800. PubMed ID: 36919876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]